Approval · Notice of Compliance 16697 · 2015
VELCADE: Notice of Compliance 16697
Issued March 16, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16697
- Date
- March 16, 2015
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: as part of combination therapy for the treatment of patients with previously untreated mantle cell lymphoma who are unsuitable for stem cell transplantation
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VELCADE | Not yet assigned | — |
Medicinal ingredients
- BORTEZOMIB MANNITOL BORONIC ESTER 3.5 MG per VIAL